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ABSTRACT
The ultimate goal of glaucoma management is
the preservation of patients’ visual function and
quality of life (QoL). The disease itself as well as
the medical or surgical treatment can have an
enormous impact on a patient’s QoL. Even the
mere diagnosis of a chronic, irreversible,
potentially blinding disorder can adversely
affect the patient’s sense of well-being and
QoL by eliciting significant anxiety. Patients
with primary open-angle glaucoma rarely
present with visual symptoms, at least early in
the course of the disease. A better
understanding of patient-reported QoL can
improve patient–physician interaction and
enhance treatment adherence by customizing
treatment options based on individual patient
profile, thus optimizing long-term prognosis.
These aspects are summarized and critically
appraised in this article.
Keywords: Glaucoma; Ophthalmology;
Quality of life; Quality of life assessment;
Visual field loss
INTRODUCTION
The World Health Organization (WHO) defines
health as ‘‘A state of complete physical, mental,
and social well-being not merely the absence of
a disease…’’. It follows that the measurement of
health and the effects of health care must
include not only an indication of changes in
the frequency and severity of diseases but also
an estimation of well-being. This can be
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assessed by measuring improvement in the
quality of life (QoL) related to health care [1].
QoL is defined as individuals’ perception of
their position in life in the context of the culture
and value systems in which they live and in
relation to their goals, expectations, standards,
and concerns. It is a wide-ranging concept
affected in a complex way by the person’s
physical health, psychological state, level of
independence, social relationships, personal
beliefs and their relationships to salient features
of their environment. QoL is thus the sum of a
range of objectively measurable life conditions
experienced by an individual. These may include
physical health, personal circumstances (wealth,
living conditions, etc.), social relationships,
functional activities and pursuits, and wider
societal and economic influences. The
subjective response to such conditions is the
domain of personal satisfaction with life. The
QoL of an individual or subgroup can be
established by comparing their position to that
of the total population [2].
Visual impairment due to ophthalmological
diseases has a negative impact on physical and
mental health and is a global concern. In the
USA, visual disability ranks among the top ten
disabilities [3]. Visually impaired people are at
higher risk than the healthy population for
accidents, social withdrawal, and depression
[4–7]. With population aging, the number of
people with visual impairment and blindness is
rapidly growing, as many eye diseases are more
prevalent among the elderly. Cataract,
glaucoma, age-related macular degeneration,
and diabetic retinopathy are the most common
causes of visual impairment [8]. In 2011,
2.71 million people in the USA had primary
open-angle glaucoma (POAG), but this number
is expected to reach 7.32 million by 2050 [9].
Several studies have examined the
relationships between different eye diseases
and QoL [10–14]. Despite substantial
differences in methodological approach, these
all concluded that visual impairment
significantly affects QoL. This review examines
the body of published literature on QoL in
patients with POAG.
METHODS
The MEDLINE database was used for the
literature search of this review. Although every
effort was made to use references as recent as
possible, articles irrespective of the year of
publication were used if deemed appropriate.
The keywords searched included glaucoma,
ocular hypertension, quality of life,
health-related quality of life, vision-related
quality of life, mental health status, visual
field damage, quality of life questionnaire,
medical therapy, and surgical therapy.
Combinations of these terms with appropriate
Boolean operators were also used. After relevant
articles were retrieved using these keywords, a
search was conducted through the literature
cited in these articles and additional papers
were identified. Abstracts of papers in languages
other than English were surveyed, too. Medical
Subject Headings (MeSH) searches were also
performed. Case reports and abstracts from
meeting presentations were not used.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
ASSESSING QUALITY OF LIFE:
STANDARD APPROACH
WHO developed two instruments to measure
QoL, the WHOQOL-100 and the
WHOQOL-BREF. Both these questionnaires
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were drafted on the basis of statements from
patients and health professionals in a wide
variety of cultures and diseases, in 15
collaborating centers around the world. Field
centers were selected to cover differences in
levels of industrialization, available health
services, and other markers relevant to the
measurement of QoL (e.g., role of the family,
perception of time, perception of self, dominant
religion) [15]. This structure means the results
of WHOQOL questionnaires are comparable
among populations in different socioeconomic
settings [16]. WHOQOL-100 and
WHOQOL-BREF have been translated into
more than 20 languages (Table 1).
The 36-Item Short Form Health Survey
(SF-36) is a short general health questionnaire
derived from a more complex survey covering
40 health facets in the Medical Outcomes Study
(MOS) [17]. The eight health concepts in the
SF-36 questionnaire were selected as
representing the most frequently measured
facets in health surveys, and those most
affected by disease and treatment. SF-36 has
three levels: (1) items; (2) eight scales,
aggregating 2–10 items each; (3) two summary
scores, aggregating the scales. All but one of the
36 items are used to score the eight scales. Three
scales (physical functioning, role-physical, and
bodily pain) are linked to the physical
component of QoL and contribute most to the
scoring of the physical component summary
measure. Mental health, emotional-role, and
social functioning scales correlate with the
patient’s psychological status and contribute
to the scoring of the mental component
summary measure.
SF-36 can separate symptomatic and
asymptomatic patients, distinguish stages and
severity of a disease, and classify treatment
effects [18–22]. The international adaptation
was done by forward and backward translation,
review by representative focus groups, and
formal evaluation of the adapted forms. In 1996
a second version of SF-36 was introduced to
correct deficiencies found in the original version.
EuroQOL-5D (EQ5D) is a generic
multidimensional questionnaire composed of
Table 1 Validated questionnaires for the assessment of quality of life in the general population and glaucoma patients
Questionnaire Brief description No.
items
Domains Validated
WHOQOL-100 World Health
Organization
questionnaire
100 General health, positive feeling, social support,
ﬁnancial resources/physical, psychological and
social relationships
Yes (in 20
languages)
WHO-BREF Short version of
WHOQOL-100
26 General health, positive feeling, social support,
ﬁnancial resources/physical, psychological and
social relationships
Yes (in 20
languages)
SF-36 Short general health
questionnaire
36 Physical component, mental health, emotional- role
and social functioning
Yes (in ten
languages)
Equation 5D Multidimensional:
descriptive system and
visual scale
5 Mobility, self-care, usual activities, pain/discomfort,
anxiety/depression
Yes (more
than 100
languages)
WHOQOL-100 World Health Organization Quality of Life-100, WHO-BREF World Health Organization-BREF, SF-36
Short Form-36, EQ5D EuroQOL-5D
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two parts: the EQ5D descriptive system and the
EQ visual scale (EQ-VAS). Five dimensions are
inspected: mobility, self-care, usual activities,
pain/discomfort, anxiety/depression. Each
dimension has three levels: no problems, some
problems, severe problems. Each answer is
converted to a one-digit number and the digits
for each dimension are combined in a five-digit
number, describing the patient’s health state.
This five-digit number is then elaborated using a
unified scoring algorithm based on time
trade-off data from several European studies
[23–25]. The EQ-VAS cards measure
self-reported general health status, using a
vertical thermometer-analogue scale, where
the endpoints are labeled ‘‘best imaginable
health state’’ and ‘‘worst imaginable health
state’’ (Fig. 1). Equation 5D has been used in
more than 3000 publications investigating QoL
in a very wide range of diseases. Its widespread
use is due to its design, suitable for
self-completion (e.g., in postal surveys), but
also useful in clinics and face-to-face interviews.
QUALITY OF LIFE IN OCULAR
HYPERTENSION AND GLAUCOMA
A revised version of the WHOQOL-BREF
questionnaire was used to assess the social
impact of eye diseases in a developing
population in Andhra Pradesh, southern India
[13]. The authors calculated a total score for
each of the questions and expressed this as a
percentage of the total possible score, from 0 to
100, with higher scores indicating better results.
Patients with glaucoma had lower mean scores
than patients without visual impairment (62.6
vs. 84.1 for glaucoma and healthy subjects,
respectively) and patients with other eye
diseases (78.1, 74.4, and 72.7 for refractive
errors, cataract and retinal diseases,
respectively). The results from this study must
obviously be interpreted taking account of the
social context of Andhra Pradesh and the
difficulties of accessing medical care. Among
patients with glaucoma 52% were bilaterally
blind and 88% were blind in at least one eye.
SF-36 was used to assess QoL in patients
enrolled in the Ocular Hypertension Treatment
Study (OHTS) [26]. This was a multicenter,
randomized, prospective clinical trial to
determine the efficacy of topical ocular
hypotensive medications in delaying or
preventing the onset of glaucoma in patients
with ocular hypertension (OHT). QoL was tested
overall and separately in African Americans and
in patients of other ethnicities, including
Caucasian, Asiatic, and Hispanic. This
distinction was made to adjust for racial
differences in socioeconomical substrate and in
the natural history of the disease, which seems
more aggressive in Africans than others. At
baseline the SF-36 profile of African Americans
did not differ from that of patients of other
ethnicities, after adjustment for demographic
factors and systemic comorbidities. Only the
physical function score was lower in African
Americans than others (p = 0.03). The SF-36
profile of the entire sample was better than age-
and sex-matched population-based norms
(p\0.001). These results probably reflect a bias
in the OHTS enrollment of patients, as it is well
known that volunteers for some studies may not
resemble the general population. OHTS
volunteers probably had a higher educational
level and socioeconomic status [26]. Baseline
demographic conditions were similar in African
Americans and subjects of other ethnicities,
justifying similar QoL scores.
Wilson et al. submitted the SF-36
questionnaire to three groups: 121 patients
with POAG, 42 patients with suspected
glaucoma, and 135 patients with no diagnosis
of ocular disease except cataract [27]. POAG
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patients had lower scores than those with
suspected glaucoma in all domains (p = 0.038)
except ‘‘general health’’ (p = 0.065). As expected,
controls had higher mean scores than patients
with POAG and suspected glaucoma on all SF-36
domains (p\0.001) except the ‘‘general mental’’
domain, where no difference was found
(p = 0.148). In this study, POAG was a strong
predictor of lower SF-36 scores in all domains.
According to these results, it seems that the mere
Fig. 1 An example of a completed EQ-VAS thermometer-analogue scale
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knowledge of having glaucoma (even without
visual field (VF) damage) can have a negative
effect on QoL [28, 29].
QoL was also assessed by Parrish et al. in 147
glaucoma patients, consecutively enrolled from a
glaucoma clinic [30]. Scores for the eight domains
of the SF-36 questionnaire were comparable with
age-adjusted normative data and no significant
difference was found. The SF-36 scores were not
greatly affected by visual acuity impairment or VF
impairment or overall visual impairment.
However, it should be noted that patients
enrolled in this study suffered from early
glaucoma, as more than 75% had less than 50%
loss of binocular VF (Esterman VF test). The SF-36
may fail to detect changes in QoL in patients at
initial stages of the disease, disclosing deficiencies
only when VF defects are more advanced.
Glaucoma is an ocular condition that does not
normally cause systemic symptoms, having no
strong impact on a patient’s perception about
general health and categories that examine this.
In a Brazilian study, glaucoma patients scored
less than controls in all the SF-36 domains, with
significant differences in all but three categories
(general health, vitality, and role-emotional)
[31]. However in that study, body pain gave the
lowest mean score, indicating very severe and
extremely limiting pain in glaucoma patients
(respectively 7.0 and 72.6 in glaucoma and
healthy patients, p\0.001). The authors
explain these results by cultural bias, as the
local population probably used pain as a generic
complaint to gain sympathy from doctors and
compassion from the family.
From a systematic review of studies that used
the SF-36 survey to evaluate QoL in glaucoma
patients, vitality was the most affected domain
(scores 37–71), and social functioning (scores
54–92) and role limitations-emotional (score
range 57–91) were the least affected [32].
General scores in the physical domains (i.e.,
physical functioning, role limitations-physical,
bodily pain, and general health) were lower
than those in the psychosocial domains (social
functioning, mental health, vitality, and role
limitations-emotional). It is not clear why
psychosocial domains are less affected than
others in glaucoma patients. One could expect
the glaucoma diagnosis and its consequences
on visual function to affect a patient
emotionally. However, it is possible that the
initial distress of glaucoma diagnosis is accepted
with time by the patient, especially when no
new symptom appears.
Kobelt et al. analyzed QoL in 199 patients
with POAG and OHT, divided into five groups
according to their disease severity [33]. Results
were expressed in terms of utility score: utilities
are preferences that patients or the general
population have for certain health states, and
the expressed scale is anchored between 1 (full
health) and 0 (death). The mean EQ5D utility
score in glaucoma patients was 0.8, which is
close to the average for the Swedish population,
where the study was run. No difference was
found in utility scores for the first four severity
stages of the disease, but the scores for stage 5
patients in at least one eye were significantly
worse (p\0.05, Fig. 2). Total visual acuity,
visual acuity in the better eye, and
comorbidity significantly affected utility scores
(p\0.05). Interestingly, QoL seems to be
Fig. 2 Utility classiﬁed in ﬁve stages based on mean
deviation in the worst eye (adapted from Kobelt et al. [33])
964 Adv Ther (2016) 33:959–981
worsened by glaucoma only in the more
advanced stages and especially when both eyes
are affected.
Similarly, Aspinall et al. found no problems
across almost all the scales of the EQ5D
questionnaire in a cohort of 84 glaucoma
patients with no other comorbidities [34].
However, scores were low in the pain scale.
These results can be explained by the fact that
11% of the enrolled patients had angle-closure
glaucoma, a typically painful condition. There
was also the stinging sensation of eye drops
(89% of patients were using topical
medications) or the pain caused by dysesthesic
conjunctival blebs in some patients following
trabeculectomy (43% had previous surgery for
glaucoma). As expected, the EQ5D summed
index score was influenced by years since
diagnosis (p\0.05), VF loss (p\0.01), and
visual acuity (p\0.01).
PATIENT-REPORTED OUTCOMES
IN GLAUCOMA
The US Food and Drug Administration (FDA)
recently recommended the use of
patient-reported outcomes (PROs) as an
umbrella term covering a broad range of health
data reported by the patient [35, 36]. Some
objective measurements used in clinical trials to
describe a disease or its severity may fall short in
capturing the impact of the disease on patients’
daily life. For example, visual acuity and VF
damage are useful to classify glaucoma stage, but
they do not describe the effect on patient daily
activities, such as driving, walking, or reading.
The patient’s point of view is important to
completely understand how glaucoma and its
treatment affect QoL, as some experience can
only be interpreted first hand.
According to a systematic review, available
PROs in glaucoma literature can be classified
into three major categories [35]: PROs
addressing functional status related to vision,
PROs addressing overall QoL, and PROs
assessing other factors related to disease and
treatment (i.e., symptoms, side effects,
adherence, satisfaction, self-efficacy) (Table 2).
The first category of PROs (i.e., those
addressing functional status related to vision)
refers to a set of questionnaires that investigate
a patient’s ability to undertake daily activities,
fulfill life roles, and perform actions designed to
maintain health and well-being [37]. All the
questionnaires describe activities that need
visual function and the patient is asked to rate
these activities as difficult or problematic. In
this category, a questionnaire was developed to
measure patients’ abilities to find their way,
walk, and travel safely and independently
(Independent Mobility Questionnaire, IMQ)
[38]. Independent mobility perceived by
glaucoma patients was associated with mean
deviation (MD) in the better eye (p\0.01) and
visual acuity in the better eye, the fellow eye,
and in both eyes (p = 0.05) [39]. In the same
category of PROs, the Glaucoma Symptom
Identifier (GSI) was designed to assess multiple
possible glaucoma symptoms and their impact
on QoL in clinical practice [40].
PROs assessing overall QoL include
questionnaires that investigate the impact of
eye diseases on QoL, as perceived by the patient.
As QoL is a multidimensional concept, PROs in
this category analyze different domains to
comprise all facets of living (from physical to
psychological ones).
The National Eye Institute Vision Function
Questionnaires (NEI-VFQ-25 and -51 items)
were developed to measure vision-targeted
functioning and influence of vision problems
on health-related QoL (HR-QoL) across several
eye conditions [41, 42]. The creation and
selection of items involved different groups of
Adv Ther (2016) 33:959–981 965
patients with glaucoma, macular degeneration,
cataract, and other eye diseases. One-third of
the patients involved in item selection had
POAG, with a wide range of severity. The
NEI-VFQ, both in the 51-item and the shorter
25-item version, have been widely used and
shown to be internally consistent [43, 44],
reproducible [43], and responsive in glaucoma
patients [44]. NEI-VFQs were used in
randomized clinical trials, such as the Early
Manifest Glaucoma Trial (EMGT) [45] and The
Tube versus Trabeculectomy Study [46].
Beside general vision-specific instruments,
PROs assessing overall QoL include several
glaucoma-specific tests, such as the Glaucoma
Quality of Life (Glau-QoL) questionnaire [47],
the Glaucoma Health Perception Index [48, 49],
and the Glaucoma Utility Index [50]. Almost all
these questionnaires include patients’ input for
item generation. They have good
developmental characteristics, with strong
evidence of validity [47].
The third category of PROs includes
questionnaires developed to assess either
topical treatment or disease-related factors that
can influence QoL. The Treatment Satisfaction
Survey-Intraocular Pressure (TSS-IOP) is
designed to evaluate patient satisfaction with
various aspects of topical medications employed
in glaucoma. The methods used to select and
organize items were adequate [51]. Although
TSS-IOP is the instrument of choice for
Table 2 Patient-reported outcome questionnaires
Questionnaire Brief description No.
items
Domains Validated
COMTOL Developed for use in clinical trials
to compare ophthalmic
medications
37 Inﬂuence of glaucoma therapy on
QoL considering frequency and
severity of common side effects
Yes (in patients
treated with
timolol and
pilocarpine)
IMQ Patient’s ability to undertake daily
activities, fulﬁll life roles, and
perform actions
35 Patients’ abilities to walk, travel safely
and independently
Yes
GSI Multiple possible glaucoma
symptoms and their impact on
QoL in clinical practice
32 Assess multiple possible glaucoma
symptoms and their impact on QoL
Yes
Glau-QoL Patients’ input in view of items
generation
36 Series of glaucoma-speciﬁc tests and
QoL
No
NEI-VFQ Instrument to assess
vision-dependent function and
QoL
51 Vision-targeted functioning and
inﬂuence of vision problems on
health-related QoL
Yes
TSS-IOP Questionnaire to evaluate patient’s
satisfaction with various aspects
of topical medications
42 Patient’s satisfaction with various
aspects of topical medication
No
COMTOL Comparison of Ophthalmic Medications for Tolerability, IMQ Independent Mobility Questionnaire, GSI
Glaucoma Symptom Identiﬁer, Glau-Qol Glaucoma Quality of Life, NEI-VFQ National Eye Institute Vision Function
Questionnaire, TSS-IOP Treatment Satisfaction Survey-Intraocular Pressure
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comparing different classes of topical
medication, validation is still lacking [51, 52].
Another instrument to evaluate the influence of
glaucoma therapy on QoL, The Comparison of
Ophthalmic Medications for Tolerability
(COMTOL) questionnaire, uses common side
effects reported by patients in clinical trials [53].
It was only validated in patients treated with
timolol and pilocarpine, so difficulties may arise
in applying it for patients who use other
therapies. Beside side effects due to topical
medication, which are extensively investigated
both by TSS-IOP and COMTOL, TSS-IOP focuses
more on patient satisfaction related to the
effectiveness of eye drops, while COMTOL
addresses daily activity limitations (e.g.,
driving) due to topical therapy.
QUALITY OF LIFE IN GLAUCOMA
PATIENTS: LOSS OF VISUAL
FUNCTION
Early detection of glaucoma is one of the
objectives stressed by glaucoma societies to
preserve visual function and patients’ QoL [54,
55]. Patients with early glaucoma often remain
undiagnosed until it progresses to advanced
stages, when central vision is affected. Several
studies have reported visual acuity loss as one of
the causes associated with lower HR-QoL in
POAG patients [33, 56, 57].
In the EMGT, the Swedish version of the
NEI-VFQ-25 was self-administered to patients 3
and 6 years after randomization [44]. At the
3-year administration, the mean composite
score (88.8) and mean subscale scores
(98.0–58.3) were generally high and there were
no differences between the treatment and
observation groups. Although the patients
showed good results in terms of QoL, NEI-VFQ
scores were correlated with low visual acuity in
the better eye, worse perimetric MD, and
nuclear lens opacities; no correlation was
found with age, sex, IOP, cardiovascular
disease, or systemic hypertension. Larger drops
in composite scores between the 3- and 6-year
NEI-VFQ were associated with greater loss in
visual acuity (p\0.05), but treatment (assigned
at randomization or later in the study) had no
effect on QoL. These results suggest that
absence or delay of treatment does not
influence vision-targeted QoL in early
glaucoma patients up to 6 years from initial
diagnosis.
A recent report from EMGT, after 20 years of
follow-up, showed that many patients with VF
loss of less than 50% (e.g., VF index 50% or MD
-18 dB) in the better eye rated their
vision-related QoL at a level similar to that
reported by patients with no VF loss in the
better eye [58]. These results support the
arbitrary, but widely used, limit of a better-eye
VF loss of less than 50% as an important
threshold for severe functional impairment.
The Collaborative Initial Glaucoma
Treatment Study (CIGTS) randomized 607
newly diagnosed patients with POAG to
treatment either with medications or
trabeculectomy (with or without
5-fluorouracil) [59]. The authors elaborated a
CIGTS-dedicated instrument consisting of a
combination of generic and disease-specific
PROs to compare patients’ QoL between
treatment groups [48]. It included 246 items,
administered to the patient by phone in about
45 min. Correlation coefficients between
disease-specific QoL measures and VF scores
were weak even if statistically significant. At
initial diagnosis, difficulty with bright lights
and difficulty with light and dark adaptation
were the most frequently reported symptoms
related to visual function, while visual
distortion was the most bothersome. Patients
were divided into three VF subgroups, derived
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from the worse eye CIGTS VF score,
representing mild, moderate, and severe VF
loss. All the means from the disease-specific
questionnaires were ranked according to the
level of the disease.
VF MD in the best eye was used in another
study to classify POAG patients into three stages
(early, moderate, and advanced) [60]. OHT
patients and healthy controls were enrolled as
well. General QoL and visual function QoL were
evaluated in each stage of the disease. No
differences were found in QoL perception
between healthy patients and OHT/early
POAG patients, showing that neither
medications nor the knowledge of having the
disease affected QoL. In contrast, a difference
was found between OHT/early and
moderate/severe glaucoma patients, with
progressive reduction in QoL perception
throughout the stages of the disease.
Three questions were strongly associated
with the gravity of the binocular VF defect in
glaucoma patients [61, 62]: (1) do you bump
into things sometimes? (2) Do you trip on
things or have difficulty with stairs? (3) Do you
have difficulty in finding things you have
dropped? These abilities appeared to be
linearly and progressively affected in the
progression of the disease, influencing QoL
more in advanced stages [61], particularly in
patients with MD less than -12 dB [62].
The Los Angeles Latino Eye Study (LALES)
was a population-based prevalence study of eye
diseases in Latinos living in Los Angeles,
California, aged 40 years and more [63]. A
total of 213 patients with POAG from a
population of 7789 participants were included
in an analysis to determine the impact of
glaucomatous VF loss on QoL [64]. HR-QoL
was assessed by the Medical Outcomes Study
12-item Short-Form Health Survey (SF12) and
the NEI-VFQ-25 questionnaire. A monotonic
correlation trend was observed between VF loss
and most NEI-VFQ-25 subscale scores, showing
that glaucoma patients with severe VF loss had
lower QoL scores than patients with no or
initial VF loss. Correlation coefficients from the
better-seeing eye were significant for 6 of the 12
NEI-VFQ subscales and the NEI-VFQ composite
score. Glaucoma patients had greatest
difficulties driving, especially in more
advanced stages of the disease. A unique
feature of this study was the ability to measure
self-reported QoL before the participants were
diagnosed with glaucoma and therefore before
they were aware of the disease. At enrollment
75% of patients affected with glaucoma were
unaware of it. Interestingly, however, the
association between QoL scores and VF loss
persisted even after controlling for knowledge
of glaucoma or when analysis was restricted to
LALES patients unaware of the disease.
An objective estimation of vision-specific
ability to perform activities of daily living and
its correlation to clinical tests (i.e., visual acuity,
visual field test, contrast sensibility, and
stereopsis) was attempted in a group of
glaucoma patients by Richman et al. [65].
These authors employed the ADREV
(Assessment of Disability Related to Vision)
test to objectively score patients’ ability to
perform daily-life actions, such as reading in
reduced illumination or recognizing facial
expressions. Interestingly, results of clinical
tests had higher correlations with ADREV than
with NEI-VFQ-25 scores. These data highlight a
potential limit of PROs, i.e., the dependency on
subjective sphere and the high variation of
responses also in patients with the same severity
of disease.
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QUALITY OF LIFE: MONOCULAR VS.
BINOCULAR VISUAL FIELD LOSS
In advanced glaucoma the areas of monocular
VF defects may coincide in the two eyes,
resulting in binocular VF loss. Central VF and
visual acuity are generally spared until the
disease is more advanced. Patients with
binocular VF loss have serious difficulties in
activities of daily life such as reading, mobility,
or driving [66–69]. However, QoL can also be
affected by VF loss in one eye independently.
The location of VF in one eye may play an
important role in patients’ QoL perception.
A cross-sectional study investigated the
relationship between VF loss and QoL in 537
OHT and POAG patients from seven hospitals in
the Netherlands [70], using MD from the 30-2
threshold program of the Humphrey Field
Analyzer to quantify monocular and binocular
VF loss. QoL was investigated with a
questionnaire containing health-generic
(EQ5D and Health Utilities Index mark 3),
vision-specific (NEI-VFQ-25), and
glaucoma-specific (Glaucoma Quality-of-Life
questionnaire, GQL-15) instruments. The
relationship between QoL scores and MD was
significant for the generic and disease-specific
QoL instruments. However, while the
relationship between VF loss and
disease-specific questionnaires was linear (QoL
declined with VF progression), the relationship
between VF loss and health-generic instruments
was not. Indeed, utility scores seemed
significantly affected by VF loss when MD in
the better eye was below -25 dB. The impact on
QoL of VF loss in the better eye was stronger
than in the worse eye. Binocular VF appeared to
be mainly determined by VF in the better eye.
The impact on QoL of VF loss in the better eye
grew in line with the VF defect in the worse eye.
Another study investigated the
vision-specific QoL in glaucoma patients on
the basis of the location of VF defects [71]. A
significant correlation was detected between
vision-specific QoL scores and clustered VF MD
in both the better and the worse eye, although
correlation coefficients were generally higher
for the better eye. The correlation coefficients
for the lower paracentral and lower peripheral
VF of the better eye were the highest for several
subscales, such as general vision, near vision,
distance vision, social function, mental health,
role limitation, and driving.
Another investigation analyzed the
association between glaucoma-induced VF
defects in the superior and inferior hemifields
and vision-related QoL [72]. Patients were
evaluated with the 24-2 SITA Standard
program of the Humphrey Visual field
Analyzer, and an integrated VF was calculated
using the best sensitivity method [73].
Vision-related QoL was evaluated using the
NEI-VFQ-25. The MD of the superior hemifield
was correlated only with near activities score
(p\0.01), while the MD of the inferior
hemifield was positively correlated with
general vision, vision-specific role difficulties,
and peripheral vision. This may explain why
patients with glaucoma and worse binocular
inferior VF have slower walking speed, higher
rates of falls, and more falls with injury among
elderly individuals [74, 75].
Data from the Diagnostic Innovations
Glaucoma Study (DIGS) were used to evaluate
the correlation between longitudinal changes in
QoL and rates of progressive VF loss [76]. A
significant correlation was found between
changes in the NEI-VFQ-25 scores during
follow-up and changes in binocular VF
sensitivity. Eyes with more severe disease at
baseline were more likely to have lower
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NEI-VFQ-25 scores during follow-up. For
patients with the same extent of binocular
sensitivity loss over time, those with shorter
follow-up had larger changes in NEI-VFQ-25
scores (p = 0.005).
MENTAL HEALTH STATUS
AND QUALITY OF LIFE
IN GLAUCOMA
Many studies have investigated the relationship
between glaucoma, anxiety, and depression
[77–86]. Although there is no actual evidence
on this topic, a higher prevalence of
psychological disorders in glaucoma patients
can be reasonably assumed. As a result of its
asymptomatic, chronic nature and potential
outcome of blindness, glaucoma often imposes
a psychological burden [79, 87]. Limitation of
life spaces due to a variety of factors, such as
driving limitations [88, 89], fear of falling [90,
91], and worse balance [82], also contribute to
the relationship between glaucoma and
depression.
The prevalence of anxiety and depression in
patients with POAG was evaluated in a
case–control study [80] using the Hospital
Anxiety and Depression Scale (HADS)
questionnaire. The prevalence of patients with
anxiety (13.0%) and depression (10.9%) was
significantly higher than in the control group
(7.0% and 5.2% respectively, p\0.05). When
glaucoma was evaluated as a potential risk
factor for anxiety and depression, a negative
correlation was found between age and the
HADS-Anxiety subscore, after adjusting for
demographic and clinical variables (p\0.01)
[81]. Interestingly, younger glaucoma patients
tended to be more anxious compared to older
ones, as demonstrated in studies on other
chronic diseases [92, 93]. As expected, older
age and decreasing MD, determined by
computerized perimetry in the better eye, were
associated with depression.
Jampel et al. investigated depression and
mood indicators in newly diagnosed POAG
patients, as a part of CIGTS [79]. At baseline
patients were interviewed by telephone and
answered three questionnaires about their
vision in daily-life activities (Visual Activity
Questionnaire, VAQ), their perception of
health (Health Perception Index, HPI), and
their depression status (eight questions from
the Center for Epidemiological Studies
Depression Scale, CES-D). Objective measures
of poorer visual function (i.e., visual acuity and
CIGTS VF) were not correlated with symptoms
of depression and poor mood, while patients’
perception of their vision (total VAQ score) was
significantly correlated to each item of the HPI
and CES-D (p B 0.001). In other words, QoL was
more affected by the way the patients perceived
their vision than the objective measurement of
it. In addition, depression itself may have led to
poorer responses to VAQ questions, acting as a
confounding factor in the analysis.
CIGTS QoL questionnaires included an
assessment of fear of blindness (FOB). As these
questionnaires were administered by trained
telephone interviewers every 6 months,
changes in FOB were assessed continuously
during the 5-year follow-up [87]. At baseline,
after being told about glaucoma diagnosis but
before randomization, 34% of patients reported
either a moderate amount or a lot of worry
about blindness (Fig. 3). This decreased to 17%
by 6 months and to 11% over a 5-year period.
Almost half the patients remained at least a
little worried 5 years after the diagnosis of
glaucoma. In multivariate analysis, younger
age, white ethnicity, low-grade education, and
lower income were significantly associated with
increased FOB (p = 0.006). The decrease in FOB
over time was probably due to the reassurance
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associated with receiving treatment, regular
clinical follow-up, adaptation to the diagnosis,
or a combination thereof.
QUALITY OF LIFE: GLAUCOMA
THERAPIES
Glaucoma treatment may influence patients’
QoL in several ways. Topical and systemic side
effects, difficulties in administering
medications, and complexity of medication
regimens are all factors that can reduce
patients’ satisfaction with their therapy [94].
Patients satisfied with therapy are more likely to
adhere to it [95], to take an active role in their
own care [96], and to continue using medical
care services [97].
Tsai et al., using patient interviews, created a
taxonomy of reasons for poor adherence in a
group of patients with glaucoma [98].
Situational/environmental tasks explained 80%
of poor compliance with therapy. The need to
take drops always at the same time and the
inability to carry medication bottles when away
from home may be decisive factors. Routines are
part of life, and changes in routine often mean a
change in QoL, especially for older patients.
Similarly, side effects of eye drops, such as
hyperemia, burning, stinging, foreign body
sensation, and blurred vision, can influence
social and environmental aspects of life besides
making the patient dissatisfied with therapy.
Jampel et al. administered a willingness to
pay questionnaire to a group of 230 patients
with glaucoma or suspected glaucoma, asking
them how much they would be willing to pay
for certain characteristics in eye drops [99].
Patients were willing to pay more for eye drops
that did not cause blurred vision (85%),
drowsiness (83%), stinging or tearing (72%), or
Fig. 3 Rates of fear of blindness over time in the Collaborative Initial Glaucoma Treatment Study (adapted from Janz et al.
[48])
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cause sexual inhibition (59%); 59% were willing
to pay more for eye drops that required
once-only dosing, instead of three times a day
regimens. On the other hand, only 26% of
patients would have paid more to obtain
branded drops instead of generic ones. Eye
drop side effects and their social/
environmental implications appeared to be
key factors in influencing glaucoma patient
QoL.
Similar results were obtained in another
study, which used a Treatment Satisfaction
Survey-Intraocular Pressure questionnaire
(TSS-IOP) [52]. This is a PRO designed to assess
patient satisfaction with various attributes of
topical ocular medications. Patient satisfaction
was correlated with perceived effectiveness of
the medicine, ocular irritation, conjunctival
hyperemia, ease and convenience of use
(p\0.001). Compliance was correlated with
perceived effectiveness of the medicine
(p\0.001), ease of use (p\0.05), and
convenience (p\0.001). When physicians
were asked to rate patient compliance, no
significant correlation was found with any
dimension of patient satisfaction (p\0.05),
showing that physicians poorly predict
patients’ own rankings of compliance.
The association between factors linked with
topical medication use and health-related QoL
was evaluated by Balkrishnan et al. in a
cross-sectional study on 358 glaucoma patients
[100]. Patients were interviewed by mail with a
48-item questionnaire, comprising the VFQ-25,
the SF12, and six questions about the use of
antiglaucoma eye drops. The daily use of more
than five medications and difficulty in using the
eye drops were negatively associated with
health-related QoL scores. In multivariate
analysis, difficulty with eye drop use remained
the only medication-related factor significantly
predictive of lower VFQ-25 and SF-12 scores.
Other studies indicated that problems with eye
drop use and complex regimens may play a role
in poor compliance [101, 102]. Claxton et al.
performed a systematic review of the medical
literature, highlighting that fewer doses per day
significantly correlated with better compliance
[103]. A study of add-on therapy also suggested
that patients prescribed a second ocular
hypotensive medication refilled their first
prescribed medication less regularly [104].
Difficulties with medication use in older
patients affected with glaucoma may have
several causes [105]. Medication bottles are
often an obstacle to treatment because of
difficulties with topical application. Moreover,
many older adults with glaucoma have
considerable comorbidity, such as arthritis,
which impairs their ability to depress the
applicators of eye drops.
QUALITY OF LIFE: OCULAR
SURFACE DISEASE
Ocular surface disease (OSD) is characterized by
an inadequate quantity of tears, an unstable tear
film secondary to poor quality of tears, ocular
surface breakdown, and/or symptoms such as
irritation, burning, foreign body sensation,
dryness, photophobia, fatigue, and fluctuating
visual acuity [106]. OSD has an estimated
prevalence of 15% among individuals older
than 65 years [107] and this rises to 59% in
patients with glaucoma [106]. The higher
prevalence among glaucoma patients is
probably due to the fact that OSD and
glaucoma both have an age-dependent
prevalence; furthermore, the antiglaucoma eye
drops and the preservative agents (especially
benzalkonium chloride, BAK) may cause
inflammation [108, 109], as well as other
anterior segment ocular diseases (allergy,
blepharitis, dry eye) [110].
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Skalicky et al. evaluated the impact of OSD on
QoL in 101 glaucoma patients and 23 controls
[111]. All completed a glaucoma-specific QoL
questionnaire (GQL-15) and an Ocular Surface
Disease Index questionnaire (OSDI). OSDI is a
12-item questionnaire designed to provide a
rapid assessment of OSD related to chronic dry
eye, its severity, and its impact on the patient’s
ability to function [112]. OSDI scores correlated
well with glaucoma severity in patients younger
than 60 years and in the 70–79 years subgroup.
Exposure to more than three BAK-preserved
drops daily was independently predictive of
OSD in multivariate analysis (p = 0.018),
underlining the causal role of preservatives in
OSD.
Another study examined the relationship
between OSD and QoL in glaucoma and OHT
patients treated with BAK-preserved eye drops
[113]. Patients were asked to complete the
NEI-VFQ25 and Glaucoma Symptom Scale
(GSS) questionnaires. This latter includes 10
ocular complaints, some of nonvisual nature
(burning/smarting/stinging, tearing, dryness,
itching, soreness/tiredness, feeling of
something in the eye: GSS Symptom score)
and some visual (blurry/dim vision, hard to see
in daylight, hard to see in the dark, halos
around lights: GSS Function score), common
among patients treated for glaucoma. OSD was
diagnosed in 97 patients (41.6%), with no
difference by sex (p = 0.55) or age (p = 0.2),
and it was significantly related to the number of
years of topical treatment (p\0.001). Patients
with OSD had significantly worse mean total
NEI-VFQ and GSS scores (p = 0.04 and
p\0.001, respectively). Punctate keratitis was
present in 70 (30%) patients and related to age
(p = 0.01) and the number of topical doses per
day (p\0.001). Patients with keratitis had
worse GSS scores as well (p\0.001).
The use of BAK-preserved medications has
been associated with the development of OSD
[114, 115]. Few studies have examined the
effects of preservative-free medications on
QoL. Some looked at OSD signs (BUT,
fluorescein staining, hyperemia) after changing
from a preserved antiglaucoma drug to a
preservative-free formulation [116–120].
However, as anterior segment signs are barely
correlated with the severity of OSD [121, 122],
no real conclusions can be drawn on this topic.
QUALITY OF LIFE IN MEDICALLY VS.
SURGICALLY TREATED GLAUCOMA
PATIENTS
The CIGTS [123] was the only study identified
by a Cochrane systematic review that examined
QoL in medically or surgically treated glaucoma
patients [124]. For this reason no firm
conclusions can be drawn on this topic.
After the first 5 years of CIGTS follow-up, the
QoL impact reported by the two treatment
groups was not different, except that patients
who underwent surgery treatment complained
more frequently of local eye symptoms
(something in the eye, eye pain, red eye,
excessive tearing, etc.) [123]. This was not
unexpected, given the presence of a filtering
conjunctival bleb in the surgical group. The
effect of surgery on eye symptoms was initially
larger, but the magnitude of this effect
decreased over time. A trend towards a
reduction of symptom frequency and
symptom bothersomeness was noted during
the follow-up in both the surgical and medical
groups. This could be related to a combination
of coping, psychological adjustment and
accommodation to the glaucoma diagnosis, or
to the actual decrease or cessation of the
particular problem.
Adv Ther (2016) 33:959–981 973
Guedes et al. examined QoL in 225 Brazilian
glaucoma patients, divided into three groups
according to their management: medical (82
patients), surgical (47 patients), and medical
plus surgical (96 patients) treatment [125]. QoL
was assessed by using the validated
Portuguese-language version of the
NEI-VFQ-25. When analysis was controlled for
confounding variables, surgery was a predictor
of poor QoL only in patients with early disease
and did not influence QoL in more advanced
cases. No difference was noted among various
glaucoma surgeries (p = 0.19).
GLAUCOMA AND DISABILITY:
WHICH TASKS OF DAILY LIFE ARE
AFFECTED?
Loss of visual function in glaucoma patients can
affect walking, venturing out from home,
reading, seeing at night, adjusting to different
levels of illumination, judging distances, and
seeing objects coming from the side [126, 127].
When glaucoma patients were asked to choose
which activities were most important among
hypothetical scenarios in which they had
different levels of difficulty with different
tasks, the greatest importance was given to
tasks involving central and near vision (i.e.,
reading), with high scores also for mobility
outside the home (i.e., driving and walking
outside) [34, 50]. Problems like glare, bumping
into objects, and household chores were
considered minor [34].
Difficulties with central and near vision tasks
in general, and with reading specifically, are the
most frequent complaint among people with
eye disease. Near vision tasks such as reading are
also the most valued visual function in those
with glaucoma. While reading is clearly
dependent on visual acuity, complaints of
difficulty reading are commonplace and were
noted in over 40% of the glaucoma patients
[69].
In the Salisbury Eye Evaluation Study (SES),
subjects with bilateral glaucoma were almost
five times more likely to report severe difficulty
with near activities than those without
glaucoma [128]. This confirms several
clinic-based studies that report more
vision-related difficulty with near vision tasks
in the presence of glaucoma-related VF loss [69].
Data from SES, however, indicated significant
discordance between measured reading speed
and self-reported reading difficulty, particularly
in people who read poorly. This disparity
between measured reading speed and
self-assessment highlights the need to use both
questionnaire and direct testing methods to
assess reading [129].
Outdoor mobility is a priority for glaucoma
patients [34, 50], and driving is the primary
means of transport among the elderly in the
USA [130]. An analysis of patients enrolled in
CIGTS showed that over 50% of driving patients
reported at least ‘‘some’’ difficulties in tasks
involving glare, while 22% reported at least
‘‘some’’ difficulties with tasks requiring
peripheral vision. Drivers with moderate
bilateral VF loss were more likely to report at
least some difficulties with all the driving tasks
investigated, compared to patients with mild or
no bilateral VF defects.
The role of binocular VF in driving tasks was
also investigated in other studies [64, 128, 131].
The SEE study found a strong correlation
between binocular VF and night driving tasks,
also after adjusting for contrast sensitivity [128].
The Los Angeles Latino Eye Study reported that
bilateral moderate to severe VF loss had a great
impact on driving tasks, while moderate to
severe unilateral VF defects had less influence
on driving capabilities [131]. The influence of
the better and worse eye on driving in patients
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with glaucoma is not completely clear.
Perceived difficulty in driving tasks seems to
increase with worsening VF damage in the
better eye [30, 69, 131].
Several studies have shown that glaucoma
patients tend to modify their driving habits, as a
result of perceiving difficulty with their vision [88,
132–135]. Discontinuation of driving was
significantly more frequent in patients with
glaucoma in both eyes, but not in one eye,
compared with healthy subjects [88]. Moreover,
when compared with people without glaucoma,
patients with glaucoma in both eyes more
frequently reported vision-related
discontinuation of driving at night, vision-related
decreased driving frequency, and vision-related
cessation of driving in unfamiliar areas.
CONCLUSION
Physicians are used to claiming the success of
glaucoma management with parameters like
IOP, visual fields, and damage progression.
However, from the perspective of the patients,
other concerns may be far more important
[136]. The most frequent problems related to
decreased vision were reading, walking on
stairs, and recognizing people. Difficulties with
these activities were more often reported by
older patients than younger ones. This is not
surprising and is probably more closely related
to age itself than to glaucomatous damage.
Assessment of QoL with a questionnaire has
several limitations. QoL assessment is
subjective: patients with similar disability may
rate their QoL differently. An inherent
limitation of QoL assessment is that
self-reported visual ability evaluated by any
questionnaire can be impaired, at least to
some extent, by other visual and systemic
morbidity or psychosocial constraints.
Conceivably, even when perimetric indices
such as MD are comparable, different
determinants such as spatial distribution and
depth of VF scotomas or speed of perimetric
deterioration may affect patients with dissimilar
lifestyles and expectations [76].
Early detection of glaucoma is a vital
objective in clinical management so that
visual function and QoL are preserved [54, 55].
Patients with early glaucoma often remain
undiagnosed until progression to advanced
stages. The present review underlines the
importance of timely glaucoma diagnosis in
preserving vision-related QoL. However, falsely
diagnosing patients as having glaucoma can
significantly reduce their QoL and well-being.
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